Xponance’s CureVac CVAC Stock Holding History

Xponance’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,964	Closed	-$326K	–	1178
2021 Q3	$326K	Sell	5,964 -95	-2%	-$5.72K	0.01%	1023
2021 Q2	$445K	Buy	+6,059	New	+$606K	0.01%	971

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Xponance's CVAC Position: Q4 2021 in Review

Xponance sold out of CureVac (CVAC) in Q4 2021, closing a stake of 5,964 shares — an estimated $326K sold.

Xponance first reported a position in CVAC in Q2 2021 and held it in 2 quarters. The position peaked at $445K in Q2 2021. 103 funds tracked by Wall St. Rank hold CVAC as of Q4 2021.

Xponance reported no remaining CureVac position as of Q4 2021 after selling out during the quarter.
Xponance sold 5,964 CureVac shares in Q4 2021, an estimated $326K.
Xponance first reported a position in CureVac in Q2 2021 and held it in 2 quarters.
Xponance's CureVac position peaked at $445K in Q2 2021.
103 funds tracked by Wall St. Rank held CureVac as of Q4 2021.

Based on Xponance's 13F filing for Q4 2021, filed 31 Jan 2022.